Non-Small Cell Lung Cancer (NSCLC)

Stage III Met - IV 2nd Line

Failed Therapy

**EGFR +**
- Failed EGFR TKI
  - TKI 1st/3rd Generation
    - LUN0090
      - Phase I/II
      - Afatinib & Necitumumab in EGFR Mutation+ NSCLC w/ 1st / 3rd Gen EGFR TKIs Acquired Resistance
      - P: Padda
      - Vanderbilt University
    - LUN0122
      - Phase I/II
      - Carboplatin + Pemetrexed + Bevacizumab in Stage IV Non-Squamous NSCLC
      - P: Wakelee
      - NCTN

**EGFR 19 or 21**
- LUN012
  - Phase I/II
  - Selective RET Inhibitor TAS0652/HM06 in Advanced Solid Tumors w/ RET Gene Abnormalities
  - P: Wakelee
  - Pending

**RET +**
- LUN0123
  - Phase I/II
  - Regorafenib in Combos w/ Oral Methotrexate in KRAS Mutated Non-Small Cell Lung Cancer (NSCLC)
  - P: Padda
  - Stanford

**ALK +**
- LUN0110
  - Phase I/II
  - P: Wakelee
  - Xcovery

**KRAS +**
- LUN0097
  - Phase II
  - Cabazitaxel in Previously Tx Stage IV or Recurrent KRAS G12C Mutated Non-Squamous NSCLC
  - P: Neel
  - ECOG-ACRIN

**MET/RET/ROS1**
- ECOG-ACRIN-EAS1501
  - Phase II
  - Cabozantinib +/- Nivolumab in Previously Treated Non-Squamous NSCLC
  - P: Neel
  - ECOG-ACRIN

**PTK7 + Study Screening**
- LUN0111
  - Phase Ib
  - Cofeuzumab Pegolotin (ABBV-647) in PTK7-Expressing Recurrent NSCLC
  - P: Neel
  - Pending